^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Triplex (CMV-MVA vaccine)

    i
    Other names: CMV-MVA vaccine, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA triplex vaccine
    Associations

    News

    Trials
    Company:
    Fortress
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P2, N=216, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Aug 2025 --> Jan 2028 | Trial primary completion date: Aug 2025 --> Jan 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)
    2ms
    Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Triplex vaccine
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)
    3ms
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2026 --> Dec 2028 | Trial primary completion date: Sep 2026 --> Mar 2028
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Triplex vaccine
    |
    CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    3ms
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2027 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Mar 2028
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    3ms
    CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, City of Hope Medical Center | Phase classification: P2 --> P1 | Trial completion date: Dec 2023 --> Jun 2024
    Phase classification • Trial completion date
    |
    Triplex (CMV-MVA vaccine)
    4ms
    CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P2, N=216, Not yet recruiting, City of Hope Medical Center | Initiation date: Dec 2023 --> Apr 2024
    Trial initiation date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)
    5ms
    Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2025 --> Apr 2030 | Trial primary completion date: Apr 2025 --> Apr 2030
    Trial completion date • Trial primary completion date • Triplex vaccine
    |
    Triplex (CMV-MVA vaccine)
    8ms
    CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P2, N=216, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)
    1year
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy • Triplex vaccine
    |
    EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    1year
    CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Blood Cancer Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • IO biomarker
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9) • LAMP2 (Lysosomal Associated Membrane Protein 2)
    |
    Triplex (CMV-MVA vaccine)
    1year
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, City of Hope Medical Center
    New P1 trial • CAR T-Cell Therapy • Triplex vaccine
    |
    EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    over1year
    Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Triplex vaccine
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)
    over1year
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    over1year
    CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Blood Cancer Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9) • LAMP2 (Lysosomal Associated Membrane Protein 2)
    |
    Triplex (CMV-MVA vaccine)
    almost2years
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, City of Hope Medical Center | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    almost2years
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, City of Hope Medical Center
    New P1 trial • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    2years
    Large-scale manufacturing and characterization of CMV-CD19CAR T cells. (PubMed, J Immunother Cancer)
    We demonstrated the feasibility of our large-scale platform for generating CMV-CD19CAR T cells for clinical application. We plan to initiate a clinical trial at City of Hope using CMV-CD19CAR T cells for patients with intermediate/high-grade B cell non-Hodgkin's lymphoma immediately after autologous hematopoietic cell transplantation followed by vaccination with a novel CMV vaccine based on Modified Vaccinia Ankara (Triplex) 28 days and 56 days post-T cell infusion.
    Journal • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    |
    CD19 expression
    |
    Triplex (CMV-MVA vaccine)
    2years
    CMV Triplex vaccine to enhance adaptive NK and T-cell reconstitution after autologous hematopoietic cell transplantation. (PubMed, Transplant Cell Ther)
    Triplex vaccine improved reconstitution of adaptive NK and CMV-specific T cells after auto-HCT in patients with lymphoma and myeloma. Further study is needed to determine the clinical impact of this modulation of immune response.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Triplex (CMV-MVA vaccine)
    2years
    Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)
    over2years
    Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. (PubMed, Int J Hematol)
    We also discuss a feasible and unique platform for the generation of the CMV-CD19CAR T cells for clinical application. This new approach would overcome multiple challenges in current CAR T cell technology including: short T cell persistence, limited duration of response, and inability to re-stimulate T cells after relapse or persistent disease.
    Preclinical • Review • Journal • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    Triplex (CMV-MVA vaccine)
    over2years
    CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Blood Cancer Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Mar 2021 --> Mar 2023 | Trial primary completion date: Mar 2021 --> Mar 2023
    Trial completion date • Trial primary completion date • IO biomarker
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Triplex (CMV-MVA vaccine)
    over3years
    Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2017 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)